FDA issues warning to drug compounding company PCCA - Milford Daily News
FDA issued a warning letter to PCCA, a major compounding outsourcing facility, for cGMP violations including sterility assurance failures. This signals increased FDA scrutiny on compounding pharmacies and 503B outsourcing facilities.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Compounding outsourcing facilities (503B), API & contract manufacturers supplying compounding pharmacies should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; FDA may conduct inspections or issue similar warnings.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA warning to PCCA highlights non-compliance with cGMP for sterile compounding, specifically lack of adequate sterility testing and environmental monitoring.
Who it affects
Compounding outsourcing facilities (503B), API & contract manufacturers supplying compounding pharmacies
What you must do
Review and enhance sterility assurance programs, ensure compliance with USP <797> and FDA guidance on compounding.
Deadline
Immediately; FDA may conduct inspections or issue similar warnings.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)